BioAv Cancer Research Results

BioAv, bioavailability: Click to Expand ⟱
Source:
Type: measurement
Bioavailability (usually in %) absorbed by the body.
CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
Scientific Papers found: Click to Expand⟱
2678- BBR,    Berberine as a Potential Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,
5731- Buty,    The Warburg Effect Dictates the Mechanism of Butyrate Mediated Histone Acetylation and Cell Proliferation
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
HDAC↓, Warburg↓, TumCP⇅, HATs↑, BioAv↓, other↝, Risk↓,
17- CBC/D,    CBC-1 as a Cynanbungeigenin C derivative inhibits the growth of colorectal cancer through targeting Hedgehog pathway component GLI 1
- in-vivo, CRC, NA
HH↓, Gli1↓, BioAv↓, TumCP↓,
4672- CUR,    An old spice with new tricks: Curcumin targets adenoma and colorectal cancer stem-like cells associated with poor survival outcomes
- vitro+vivo, CRC, HCT116
CSCs↓, Nanog↓, BioAv↓,
3578- CUR,  SIL,    Curcumin, but not its degradation products, in combination with silibinin is primarily responsible for the inhibition of colon cancer cell proliferation
- in-vitro, CRC, DLD1
eff↑, BioAv↓, TumCG↓,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↝, 1,   Warburg↓, 1,  

Cell Death ⓘ

Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Telomerase↓, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 1,   other↝, 1,  

Protein Folding & ER Stress ⓘ

GRP78/BiP↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   EMT↓, 1,   Gli1↓, 1,   HDAC↓, 1,   HH↓, 1,   mTOR↝, 1,   Nanog↓, 1,   p‑STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

E-cadherin↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   TumCP⇅, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   p‑JAK2↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 1,   eff↑, 1,   eff↝, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   GutMicro↑, 1,  

Functional Outcomes ⓘ

Risk↓, 1,  
Total Targets: 42

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: BioAv, bioavailability
2 Curcumin
1 Berberine
1 Butyrate
1 Cynanbungeigenin C (CBC) and D (CBD)
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:6  Cells:%  prod#:%  Target#:792  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page